1. Home
  2. PRG vs NEO Comparison

PRG vs NEO Comparison

Compare PRG & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$38.52

Market Cap

1.3B

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$11.15

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
NEO
Founded
2020
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Precision Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
PRG
NEO
Price
$38.52
$11.15
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$50.00
$13.38
AVG Volume (30 Days)
365.0K
1.3M
Earning Date
04-29-2026
04-28-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
0.89
N/A
Revenue
$2,409,223,000.00
N/A
Revenue This Year
$23.77
$10.63
Revenue Next Year
$7.91
$9.73
P/E Ratio
$41.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.80
$4.72
52 Week High
$41.14
$13.74

Technical Indicators

Market Signals
Indicator
PRG
NEO
Relative Strength Index (RSI) 63.12 64.32
Support Level $32.30 $7.50
Resistance Level $38.57 $11.41
Average True Range (ATR) 1.48 0.57
MACD 0.13 0.10
Stochastic Oscillator 77.00 74.25

Price Performance

Historical Comparison
PRG
NEO

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: